Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

ClinicalTrials.gov ID: NCT06922591

Public ClinicalTrials.gov record NCT06922591. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

Study identification

NCT ID: NCT06922591
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Tango Therapeutics, Inc.; Industry
Enrollment: 183 participants

Conditions and interventions

Conditions

Interventions

RMC-6236 Drug
RMC-9805 Drug
TNG462 Drug
gemcitabine/nab-paclitaxel Drug
mFOLFIRINOX Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 30, 2025
Primary completion: May 31, 2027
Completion: Nov 30, 2027
Last update posted: Apr 21, 2026

2025 – 2027

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 16

Facility	City	State	ZIP	Site status
Mayo Clinic Scottsdale	Scottsdale	Arizona	85259-5452	Recruiting
Sarah Cannon Research Institute Denver	Denver	Colorado	80218	Recruiting
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	Recruiting
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	Recruiting
Northwestern Memorial Hospital	Chicago	Illinois	60611-2908	Recruiting
University of Indiana	Indianapolis	Indiana	46202	Recruiting
University of Iowa Health Care	Iowa City	Iowa	52242	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02115	Recruiting
Mayo Clinic Cancer Center	Rochester	Minnesota	55905-0001	Recruiting
Nebraska Cancer Specialists	Omaha	Nebraska	68124	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	11065	Recruiting
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599-7305	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
NEXT Dallas	Irving	Texas	74039	Recruiting
Huntsman Cancer Institute, University of Utah	Salt Lake City	Utah	84112	Recruiting
NEXT Oncology	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06922591, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 21, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06922591 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →